https://cytonics.com/press-releases/cytonics-announces-launch-of-regulation-a-equity-crowdfunding-campaign-to-fund-phase-2-development/2025-05-26T03:59:41-04:00https://cytonics.com/press-releases/cytonics-announces-successful-completion-of-phase-1-study-for-first-nine-patients-in-cyt-108-clinical-trial/2025-05-26T03:57:00-04:00https://cytonics.com/press-releases/cytonics-announces-completion-of-enrollment-for-phase-1-clinical-study-evaluating-cyt-108-a-novel-recombinant-protease-inhibitor-in-patients-suffering-from-osteoarthritis-of-the-knee/2025-05-26T03:56:23-04:00https://cytonics.com/press-releases/cytonics-announces-initiation-of-first-in-human-phase-1-clinical-study-for-cyt-108-in-patients-suffering-from-osteoarthritis-of-the-knee/2025-05-26T03:55:46-04:00